Iterum Therapeutics PLC
Iterum Therapeutics plc (ITRM) is a small, clinical‑stage pharmaceutical company focused on developing anti‑infective treatments to address bacterial infections. With a market capitalisation of roughly $35 million, Iterum is a micro‑cap where value often depends on clinical trial results, regulatory progress and access to funding. The company’s prospects can be materially affected by binary events such as trial readouts or approval decisions, and it may rely on partnerships or capital raises to advance programmes. Shares can be thinly traded and prone to volatility, so liquidity and dilution risks are important considerations. This summary is for general educational purposes and not personalised investment advice — investors should review the company’s latest filings, monitor operational updates and consult a regulated financial adviser before making investment decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Iterum Therapeutics' stock with a target price of $6.50, indicating significant growth potential.
Financial Health
Iterum Therapeutics is generating moderate cash flow per share, indicating steady financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ITRM
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical catalysts ahead
Trial readouts and regulatory decisions can move value materially, though outcomes are binary and may cause sharp share‑price swings.
Antibiotic development focus
Works on anti‑infective treatments addressing resistant bacteria — an area with medical need but known regulatory and commercial hurdles.
Capital and liquidity
Micro‑cap status means thin trading and potential funding needs; watch cash runway and any planned capital raises.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
